B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GALNT14

MOLECULAR TARGET

polypeptide N-acetylgalactosaminyltransferase 14

UniProt: Q96FL9NCBI Gene: 796231 compounds

GALNT14 (polypeptide N-acetylgalactosaminyltransferase 14) is targeted by 1 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GALNT14

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1urolithin d0.691

About GALNT14 as a Drug Target

GALNT14 (polypeptide N-acetylgalactosaminyltransferase 14) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 1 compounds with documented GALNT14 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GALNT14 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.